

N.B. This is an unofficial translation of the Swedish original wording. In case of differences between the English translation and the Swedish original, the Swedish text shall prevail.



NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

The form must be received by Isofol Medical AB (publ) not later than 22 February 2023.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Isofol Medical AB (publ), Reg. No. 556759-8064 at the extraordinary general meeting on 28 February 2023. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): The undersigned solemnly declare that the enclosed power of attorney corresponds to the original and has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions

- Complete all the requested information above
- Select the preferred voting options below

- Print, sign and send the form by post to Isofol Medical AB (publ), “EGM II 2023”, Att. Gustaf Albèrt, Arvid Wallgrens backe 20, SE-413 46 Gothenburg, Sweden, or via e-mail to 28febextrastamma@isofolmedical.com
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions for this is included in the notice convening the general meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The advance voting form, together with any enclosed authorisation documentation, shall be received by Isofol Medical AB (publ) not later than 22 February 2023. An advance vote can be withdrawn up to and including 28 February 2023 by contacting Isofol Medical AB (publ) via e-mail to 28febextrastamma@isofolmedical.com.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Isofol Medical AB (publ) will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder casts votes during the general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting during the general meeting, the submitted advance vote will be replaced by the vote cast at the general meeting.

Note that the advance vote does not constitute a notification to participate in the general meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the general meeting at the venue in person or represented by a proxy are included in the notice convening the meeting.

For the complete proposals, kindly refer to the notice convening the general meeting and the company’s website.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear’s website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Extraordinary general meeting in Isofol Medical AB (publ) on 28 February 2023

The options below comprise the submitted proposals included in the notice convening the general meeting and are held available on the company's website.

2. Election of chairperson at the general meeting
Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda
Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination of whether the general meeting has been duly convened
Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Determination of the number of members of the board of directors
Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Determination of remuneration to the board of directors
Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Election of members of the board of directors and chairman of the board of directors
Election of members of the board of directors
9a. Mats Franzén
Yes <input type="checkbox"/> No <input type="checkbox"/>
9b. Jonas Pedersén
Yes <input type="checkbox"/> No <input type="checkbox"/>
9c. Jan-Eric Österlund
Yes <input type="checkbox"/> No <input type="checkbox"/>
Election of chairman of the board of directors
9d. Mats Franzén
Yes <input type="checkbox"/> No <input type="checkbox"/>